News

Learning to Live with Low Vision: One Man’s Journey Through Rehabilitation

Posted on by droberts
<span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span> Learning to Live With Low Vision: One Man's Journey Through Rehabilitation Transcript (Free distribution allowed with proper credit given) This is a dramatization of the experiences of Jim, a fictional participant in a low [Read More]

New Anti-Ang2 Drug for Wet AMD Showing Promise

Posted on by droberts

It was reported here in November 2017 that two “anti-Ang2” drugs are being studied as potential combination therapies with established anti-VEGF treatments. RG7716 is being tested in combination with Lucentis (Genentech), and nesvacumab (REGN910) is being tested in combination with Eylea (Regeneron). Genentech has now reported that its Phase 2 BOULEVARD trials with RG7716 have [Read More]

First AMD Patient Receives Sub-Retinal Implant

Posted on by droberts

(Updated 4/17/18) Pixium Vision has announced its first successful human implantation of a wireless sub-retinal implant in a patient with atrophic dry age-related macular degeneration (AMD). So far, three patients have been implanted with the device, and results are promising. As reported here in October 2017, the implant, called PRIMA, acts like a tiny solar [Read More]

Apellis Entering Phase 3 Trials for Dry Macular Degeneration

Posted on by droberts

Apellis Pharmaceuticals has announced that it has finalized the trial design for its planned Phase 3 program evaluating APL-2 for the treatment of patients with geographic atrophy (GA), aka dry macular degeneration. The Phase 3 program, planned to begin in the second half of 2018, will consist of two identical studies to assess the efficacy [Read More]

1 … 39 40 41 42 43 … 107